Imatinib mesylate (Gleevec) induced unilateral optic disc edema

Optometry and Vision Science

Volumn 89, Issue 10, 2012, Pages

  Deluca, Crystal ^a   Shenouda Awad, Nancy ^b   Haskes, Charles ^b   Wrzesinski, Stephen ^b,c  

^a Western Iowa Health Care System Lincoln   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Gastrointestinal stromal tumors (GISTs); Imatinib mesylate (Gleevec); Optic disc edema; Toxic optic neuropathy

Indexed keywords

CASE REPORTS; CHRONIC MYELOGENOUS LEUKEMIA; CLINICAL HISTORY; EPIPHORA; GASTROINTESTINAL STROMAL TUMORS; GLEEVEC; IMATINIB MESYLATE; MULTI-DISCIPLINARY APPROACH; OCULAR DISEASE; OPTIC DISC; OPTIC NEUROPATHIES; SIDE EFFECT;

CHEMOTHERAPY; TUMORS;

PATIENT TREATMENT;

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; DRUG EFFECT; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HUMAN; MALE; OPTIC DISK; PAPILLEDEMA; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; OPTIC DISK; PAPILLEDEMA; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84867019657     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/OPX.0b013e318269111d     Document Type: Article

References (23)

1. Laurini JA, Carter JE. Gastrointestinal stromal tumors: a review of the literature. Arch Pathol Lab Med 2010;134:134-41.
2. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003;90:332-9. (Pubitemid 36324113)
3. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50-9. (Pubitemid 32140424)
4. Zhu J, Yang Y, Zhou L, Jiang M, Hou M. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer 2010;10:199.
5. Cohen MH, Farrell A, Justice R, Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Oncologist 2009;14: 174-80.
6. Govind Babu K, Attili VS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 2007;27:43-4. (Pubitemid 46672145)
7. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003;19:371-5. (Pubitemid 37013010)
8. Dogan SS, Esmaeli B. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009;23:109-14, ix.
9. Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res 2008;32:1022-5. (Pubitemid 351514790)
10. Kusumi E, Arakawa A, Kami M, Kato D, Yuji K, Kishi Y, Murashige N, Miyakoshi S, Ueyama J, Morinaga S, Taniguchi S, Muto Y. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia 2004;18:1138-9. (Pubitemid 38786973)
11. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of imatinib mesylate (Gleevec). Jpn J Ophthalmol 2008;52: 331-3.
12. Kanski JJ. Clinical Ophthalmology: A Systematic Approach, 6th ed. Edinburgh, UK: Elsevier Butterworth-Heinemann; 2007.
13. Sadun A, Gurkan S, Patel V. Hereditary, nutritional, and toxic optic atrophies. In: Yanoff M, Duker JS, eds. Ophthalmology, 3rd ed. Edinburgh: Mosby Elsevier; 2009:976-9.
14. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002;346:683-93. (Pubitemid 34815874)
15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80. (Pubitemid 34879334)
16. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32. (Pubitemid 351264358)
17. Rosai J. Gastrointestinal stromal tumor and its mimics. Int J Surg Pathol 2010;18:79S-87S.
18. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277:242-5. (Pubitemid 27446080)
19. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, Planck SR, Rosenbaum JT. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994;35:3649-63. (Pubitemid 24337978)
20. Biswas SK, Zhao Y, Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15: 1599-610.
21. Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg 2005;31:2427-8. (Pubitemid 43212940)
22. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist 2010;15:300-7.
23. Radaelli F, Vener C, Ripamonti F, Iurlo A, Colombi M, Artoni A, Reda G, Deliliers GL. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol 2007;86:390-3.